A new drug significantly improves hot flashes and night sweats in women diagnosed with breast cancer. Breast cancer is the most common cancer among women. However, its appearance is also possible in men. This type of tumor develops from the cells of the mammary gland, and depending on the place of its origin, it can be divided into ductal and lobular. The effectiveness of a newly developed drug for different breast cancer symptoms is being tracked using a study led by Monash University. The name used for the medication is Q-122. Through the development of Q-122, the researchers aim to introduce a new non-hormonal oral therapy for the treatment of vasomotor symptoms such as night sweats and hot flashes in women taking endocrine drugs for breast cancer. The drug is in a phase II clinical trial that is multicenter, randomized, double-blind, and placebo-controlled. It included 131 women on endocrine therapy, taking tamoxifen or an aromatase inhibitor, for their carcinoma. More than 75% of breast cancers are hormone sensitive and endocrine therapy is the standard method of treatment. In women with hormone-sensitive breast cancer, the recommended duration of endocrine therapy is 5-10 years to prevent recurrence of the disease. However, approximately 70% of women taking endocrine therapy have vasomotor symptoms, leading to premature discontinuation of endocrine therapy in over a third of those affected. A clinical trial found that Q-122 therapy significantly reduced the frequency and severity of moderate and severe vasomotor symptoms, which improved quality of life compared to placebo. Q-122 is well tolerated and does not cause serious side effects. Administration of this medicinal substance can significantly improve the condition of women affected by breast cancer. With its help, hot flashes and night sweats are reduced, which in turn significantly improves the quality of the patients’ sleep. Information about the newly developed medication was published in The Lancet magazine. References: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01977-8/fulltext